Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 3/20 | 0.54 |
| ▸ | JAK2 | O60674 | 2/20 | 0.54 |
| ▸ | JAK3 | P52333 | 1/20 | 0.54 |
| ▸ | CHEK1 | O14757 | 11/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2278223 | 1.00 | IKBKB (0.54) | IKBKBJAK2JAK3CHEK1MEN1 | |
| SCHEMBL2278196 | 1.00 | IKBKB (0.54) | IKBKBJAK2JAK3CHEK1MEN1 | |
| SCHEMBL2280739 | 1.00 | IKBKB (0.54) | IKBKBJAK2JAK3CHEK1MEN1 | |
| SCHEMBL2283053 | 0.94 | IKBKB (0.55) | IKBKBJAK2JAK3CHEK1MEN1 | |
| SCHEMBL2338849 | 0.94 | IKBKB (0.55) | IKBKBJAK2JAK3CHEK1MEN1 | |
| SCHEMBL2283093 | 0.94 | IKBKB (0.55) | IKBKBJAK2JAK3CHEK1MEN1 | |
| SCHEMBL2345748 | 0.88 | IKBKB (0.43) | IKBKBJAK2JAK3CHEK1MEN1 | |
| SCHEMBL2345709 | 0.88 | IKBKB (0.43) | IKBKBJAK2JAK3CHEK1MEN1 | |
| SCHEMBL2345734 | 0.88 | IKBKB (0.43) | IKBKBJAK2JAK3CHEK1MEN1 | |
| SCHEMBL2347791 | 0.88 | CHEK1 (0.49) | IKBKBJAK2JAK3CHEK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2078007-B1 | IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2011-08-31 | — | — | EP | claimed |
| US-8003695-B2 | IKK-beta serine-threonine protein kinase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-08-23 | — | — | US | disclosed |
| US-20100087515-A1 | IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS | Chroma Terapeutics Ltd (GB) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087515-A1 | IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS | IRAK3, IKBKE, IRAK1 | IKBKB 5/4885JAK2 984/4885JAK3 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.